Melody Cobleigh to Humans
This is a "connection" page, showing publications Melody Cobleigh has written about Humans.
Connection Strength
0.554
-
Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial. J Clin Oncol. 2021 07 20; 39(21):2367-2374.
Score: 0.042
-
Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs. Clin Cancer Res. 2020 03 01; 26(5):1105-1113.
Score: 0.039
-
Somatic loss of PIK3R1 may sensitize breast cancer to inhibitors of the MAPK pathway. Breast Cancer Res Treat. 2019 Sep; 177(2):325-333.
Score: 0.037
-
Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs. Clin Cancer Res. 2019 04 15; 25(8):2433-2441.
Score: 0.036
-
HER2-directed treatment of metastatic breast cancer: unanswered questions. Oncology (Williston Park). 2013 Mar; 27(3):176, 178, 180.
Score: 0.024
-
Adjuvant endocrine therapy for breast cancer. Oncology (Williston Park). 2012 Jun; 26(6):541-7, 550, 552 passim.
Score: 0.023
-
Targeting metastatic and advanced breast cancer. Semin Oncol Nurs. 2007 Feb; 23(1):37-45.
Score: 0.016
-
The challenging estrogen receptor-negative/ progesterone receptor-negative/HER-2-negative patient: a promising candidate for epidermal growth factor receptor-targeted therapy? Breast J. 2006 Jul-Aug; 12(4):360-2.
Score: 0.015
-
Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res. 2005 Dec 15; 11(24 Pt 1):8623-31.
Score: 0.015
-
A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol. 2003 Oct; 30(5 Suppl 16):117-24.
Score: 0.013
-
Is trastuzumab every three weeks ready for prime time? J Clin Oncol. 2003 Nov 01; 21(21):3900-1.
Score: 0.013
-
Impact of the 2018 ACR Supplemental Screening Recommendations on MRI Eligibility in Breast Cancer Survivors. J Am Coll Radiol. 2023 01; 20(1):71-78.
Score: 0.012
-
The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer. Clin Cancer Res. 2022 04 01; 28(7):1258-1267.
Score: 0.011
-
Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry. Breast Cancer Res Treat. 2021 Jul; 188(1):179-190.
Score: 0.011
-
Paired tumor sequencing and germline testing in breast cancer management: An experience of a single academic center. Cancer Rep (Hoboken). 2020 12; 3(6):e1287.
Score: 0.010
-
Managing menopausal problems. Cancer Treat Res. 2000; 103:1-23.
Score: 0.010
-
Trastuzumab-induced cardiac toxicity: Is serial assessment of left ventricular ejection fraction during treatment necessary? Breast J. 2020 05; 26(5):1085-1086.
Score: 0.010
-
De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry. Oncologist. 2020 02; 25(2):e214-e222.
Score: 0.010
-
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999 Sep; 17(9):2639-48.
Score: 0.009
-
Olaparib-Induced Severe Folate Deficiency in a Patient With Advanced Ovarian Cancer. J Oncol Pract. 2019 07; 15(7):405-407.
Score: 0.009
-
Hormone replacement therapy and high S phase in breast cancer. JAMA. 1999 Apr 28; 281(16):1528-30.
Score: 0.009
-
Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families? PLoS One. 2018; 13(4):e0195497.
Score: 0.009
-
Hormone replacement therapy and nonhormonal control of menopausal symptoms in breast cancer survivors. Cancer Treat Res. 1998; 94:209-30.
Score: 0.008
-
Cardiovascular Monitoring With Trastuzumab Therapy: How Frequent Is Too Frequent? JAMA Oncol. 2016 Sep 01; 2(9):1123-4.
Score: 0.008
-
Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer. Ann Oncol. 2016 06; 27(6):1029-1034.
Score: 0.007
-
Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin. Breast Cancer Res Treat. 2016 Feb; 156(1):33-43.
Score: 0.007
-
Estrogen replacement therapy in breast cancer survivors. A time for change. Breast Cancer Committees of the Eastern Cooperative Oncology Group. JAMA. 1994 Aug 17; 272(7):540-5.
Score: 0.007
-
Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. Br J Cancer. 2014 Sep 09; 111(6):1241-8.
Score: 0.007
-
Breast cancer and fenretinide, an analogue of vitamin A. Leukemia. 1994; 8 Suppl 3:S59-63.
Score: 0.006
-
Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43. Breast Cancer Res Treat. 2013 Nov; 142(2):415-21.
Score: 0.006
-
Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer. J Clin Oncol. 1993 Mar; 11(3):474-7.
Score: 0.006
-
Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. Clin Cancer Res. 2013 Mar 01; 19(5):1281-9.
Score: 0.006
-
Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin Cancer Res. 2011 Jan 15; 17(2):372-81.
Score: 0.005
-
ACR appropriateness criteria on postmastectomy radiotherapy expert panel on radiation oncology-breast. Int J Radiat Oncol Biol Phys. 2009 Mar 15; 73(4):997-1002.
Score: 0.005
-
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol. 2008 Oct 01; 26(28):4672-8.
Score: 0.004
-
Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat. 2009 May; 115(1):115-21.
Score: 0.004
-
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008 Apr 10; 26(11):1810-6.
Score: 0.004
-
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007 Dec 27; 357(26):2666-76.
Score: 0.004
-
Primary culture of squamous head and neck cancer with and without 3T3 fibroblasts and effect of clinical tumor characteristics on growth in vitro. Cancer. 1987 May 15; 59(10):1732-8.
Score: 0.004
-
Phase II study of etoposide in previously untreated squamous cell carcinoma of the head and neck. Cancer Treat Rep. 1987 Mar; 71(3):321-2.
Score: 0.004
-
Are tri-ethnic low-income women with breast cancer effective teachers of the importance of breast cancer screening to their first-degree relatives? Results from a randomized clinical trial. Breast J. 2007 Jan-Feb; 13(1):19-27.
Score: 0.004
-
Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006 Jun 20; 24(18):2786-92.
Score: 0.004
-
A phase II study of Adriamycin in previously untreated squamous cell carcinoma of the head and neck. Cancer. 1985 Dec 01; 56(11):2573-5.
Score: 0.004
-
Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA. 2005 Oct 19; 294(15):1925-33.
Score: 0.004
-
Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer. 2005 Aug; 6(3):240-6.
Score: 0.004
-
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005 Feb 01; 23(4):792-9.
Score: 0.003
-
Determination of factors associated with hospitalization in breast cancer survivors. Oncol Nurs Forum. 2004 Nov 16; 31(6):1081-8.
Score: 0.003
-
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005 Jan 20; 23(3):619-29.
Score: 0.003
-
A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer. Clin Cancer Res. 2004 Mar 15; 10(6):1971-5.
Score: 0.003
-
American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. J Clin Oncol. 2003 Jul 01; 21(13):2597-9.
Score: 0.003
-
Predictors of lymph node metastasis in T1 breast carcinoma, stratified by patient age. Breast J. 2002 Nov-Dec; 8(6):349-55.
Score: 0.003
-
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol. 2002 Aug 01; 20(15):3317-27.
Score: 0.003
-
A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer. Ann Oncol. 2002 Aug; 13(8):1220-4.
Score: 0.003
-
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002 Feb 01; 20(3):719-26.
Score: 0.003
-
Self-reported dietary habits, overall dietary quality and symptomatology of breast cancer survivors: a cross-sectional examination. Breast Cancer Res Treat. 2002 Jan; 71(2):113-23.
Score: 0.003
-
First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report. Eur J Cancer. 2001 Jan; 37 Suppl 1:S25-9.
Score: 0.003
-
First-line Herceptin monotherapy in metastatic breast cancer. Oncology. 2001; 61 Suppl 2:37-42.
Score: 0.003
-
Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol. 1997 Mar; 15(3):974-86.
Score: 0.002
-
Tandem peripheral blood progenitor cell transplants as initial therapy for metastatic breast cancer. Biol Blood Marrow Transplant. 1995 Nov; 1(1):40-6.
Score: 0.002
-
Should multicentric disease be an absolute contraindication to the use of breast-conserving therapy? Int J Radiat Oncol Biol Phys. 1994 Aug 30; 30(1):49-53.
Score: 0.002
-
Treatment of metastatic breast cancer with a split-course high-dose chemotherapy regimen and autologous bone marrow transplantation. J Clin Oncol. 1994 Feb; 12(2):342-6.
Score: 0.002
-
Sequential transplants using mobilized peripheral blood progenitor cells. J Clin Apher. 1994; 9(3):176-82.
Score: 0.002
-
Phase II trial of fludarabine phosphate in advanced renal cell carcinoma: an Illinois Cancer Council Study. Invest New Drugs. 1989 Jul; 7(2-3):251-3.
Score: 0.001
-
Phase II trial of spirogermanium in advanced non-small cell lung cancer. An Illinois Cancer Council Study. Invest New Drugs. 1989 Jul; 7(2-3):223-4.
Score: 0.001
-
Phase II trial of aminothiadiazole in advanced non-small cell lung cancer. Cancer Treat Rep. 1986 Mar; 70(3):417-8.
Score: 0.001
-
Phase II trial of bisantrene for unresectable non-small cell bronchogenic carcinoma: an Illinois Cancer Council study. Cancer Treat Rep. 1983 Sep; 67(9):841-2.
Score: 0.001
-
Endodermal sinus tumor of the mediastinum. Cancer. 1982 Aug 15; 50(4):766-74.
Score: 0.001